CGTX

Cognition Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↑ 7/10
  • Momentum↑ 8/10
Cognition Therapeutics sales and earnings growth
CGTX Growth
Good
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 50.52%
  • FCF Y/Y↓ -15.45%
Cognition Therapeutics gross and profit margin trends
CGTX Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↑ 728.50%
Cognition Therapeutics net debt vs free cash flow
CGTX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -2151.8

Cognition Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗